ILTOO Pharma announces that ILT-101 has achieved Orphan Drug Designation

ILTOO Pharma SAS today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation (ODD) status for ILT-101, the company’s lead drug for the treatment of amyotrophic lateral sclerosis (ALS).